Jolmo Capital
VC Fund
Nanjing, China
Jolmo Capital is an investment firm that provides related capital management and advisory services to new industries. As a diversified firm, Jolmo helps assist enterprises with rapid growth primarily through venture capital and in collaboration with other financial instruments.Jolmo Capital was founded in 2004 and is based in Nanjing, JiangsuProvince in China.
- Total investments:
- 59
- Last investment:
- Lead investor:
- 39%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Jolmo Capital invests in
Stages Jolmo Capital invests in
Countries Jolmo Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Health Care 14 (24%)
- Manufacturing 12 (20%)
- Medical 10 (17%)
- Biotechnology 10 (17%)
- Robotics 6 (10%)
Stage
- Series A 21 (36%)
- Series B 13 (22%)
- Seed 10 (17%)
- Angel 2 (3%)
- Series C 2 (3%)
Country
- China 50 (85%)
- Japan 1 (2%)
- United States 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jiang Guosheng
Partner
|
Partner | Total investments: 1 | Find email | |
|
Sun Haishun
Vice President of Investment
|
Vice President of Investment | Total investments: 1 | Find email | |
|
Wang Qun
head
|
head | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Xunlin Technology
|
Xunlin Technology is a metallizing technology company that specializes in surface metallization of ceramic and glass electronic substrates. | $29.6M / Series B / Aug 04, 2026 | |
| Ractigen is an early-stage pharmaceutical company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery made at the University of California San Francisco (UCSF) known as RNA activation(RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need. | $31M / Venture - Series Unknown / Jul 29, 2026 | ||
| Aokun Technology is a high-tech enterprise specializing in aviation engineering research and development (R&D) and certification services. The company provides enabling systems and solutions that focus on the integration, innovation, and application of aviation engineering and digital technology. | Series A / Jul 15, 2026 | ||
MyoGene Life Sciences
|
MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair. | Series B / Jun 24, 2026 | |
Xingneng Xuanguang
|
Xingneng Xuanguang is a fusion energy company that specializes in the development of advanced field reverse magnetic mirror fusion path technology. | $73.9M / Series A / Jun 12, 2026 | |
| Xinmaide focuses on the specialized fields of pulmonary drug delivery, nasal drug delivery, and brain drug delivery devices, dedicating its efforts to the research, design, and development of advanced medical technologies that improve how drugs are administered and absorbed in the body. | $43.7M / Series B / Apr 07, 2026 | ||
| Provider of an intellectual property service platform. The company's platform uses big data and cloud computing to integrate intellectual property data resources such as trademark, patent and copyright, enabling users from different industries to protect and promote innovation. | $58.2M / Series C / Mar 12, 2026 | ||
|
Magic Atom
|
Magic Atom is a robotics company that specializes in the development and application of robots and embodied intelligent technologies. | $72.2M / Series A / Mar 09, 2026 | |
GigaAI
|
Excellent Vision is a spatial intelligence company focused to transforming video creation into a 4D world model, enabling AI big models to grasp, generate, and reason about 4D space. | $145.1M / Series B / Mar 05, 2026 | |
|
Lovis
|
Lovis focuses on high-precision five-axis CNC machining services, serving clients in multiple high-end manufacturing sectors by delivering complex, tight-tolerance components with exceptional accuracy, surface quality, and reliability for industries such as aerospace, medical devices, automotive, and advanced equipment manufacturing. | Series A / Jan 26, 2026 | |
| See all 59 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Jolmo Capital invest in?
Jolmo Capital invests primarily in Health Care, Manufacturing and Medical startups, most often at Series A and Series B stage. Most of the 59 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jolmo Capital?
Public channels for Jolmo Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Jolmo Capital?
The team at Jolmo Capital includes Jiang Guosheng (Partner), Sun Haishun (Vice President of Investment) and Wang Qun (head). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
